Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome

References

• Matsuda Y, Toma Y, Ogawa H, et al. Importance of left atrial function in patients with myocardial infarction. Circulation. 1983;67(3):566–571. doi: 10.1161/01.cir.67.3.566.
   PubMed Web of Science ®Google Scholar
• Pathan F, D'Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007.
   PubMed Web of Science ®Google Scholar
• Thomas L, Marwick TH, Popescu BA, et al. Left atrial structure and function, and left ventricular diastolic dysfunction. J Am Coll Cardiol. 2019;73(15):1961–1977. doi: 10.1016/j.jacc.2019.01.059.
   PubMed Web of Science ®Google Scholar
• Hoit BD. Left atrial size and function. J Am Coll Cardiol. 2014;63(6):493–505. doi: 10.1016/j.jacc.2013.10.055.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2019;32(1):1–64. doi: 10.1016/j.echo.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Morris DA, Belyavskiy E, Aravind-Kumar R, et al. Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction. JACC Cardiovasc Imaging. 2018;11(10):1405–1415. doi: 10.1016/j.jcmg.2017.07.029.
   PubMed Web of Science ®Google Scholar
• Ye Z, Miranda WR, Yeung DF, et al. Left atrial strain in evaluation of heart failure with preserved ejection fraction. J Am Soc Echocardiogr. 2020;33(12):1490–1499. doi: 10.1016/j.echo.2020.07.020.
   PubMed Web of Science ®Google Scholar
• Singh A, Addetia K, Maffessanti F, et al. LA strain for categorization of LV diastolic dysfunction. JACC Cardiovasc Imaging. 2017;10(7):735–743. doi: 10.1016/j.jcmg.2016.08.014.
   PubMed Web of Science ®Google Scholar
• Potter EL, Ramkumar S, Kawakami H, et al. Association of asymptomatic diastolic dysfunction assessed by left atrial strain with incident heart failure. JACC Cardiovasc Imaging. 2020;13(11):2316–2326. doi: 10.1016/j.jcmg.2020.04.028.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar
• Figtree GA, Rådholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2019;139(22):2591–2593. doi: 10.1161/CIRCULATIONAHA.119.040057.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142(23):2205–2215. doi: 10.1161/CIRCULATIONAHA.120.050255.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063.
   PubMed Web of Science ®Google Scholar
• Gottlieb SH. Heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;78(20):2013–2016. doi: 10.1016/j.jacc.2021.09.015.
   PubMed Web of Science ®Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574. doi: 10.1038/s41591-021-01659-1.
   PubMed Web of Science ®Google Scholar
• Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19(8):71. doi: 10.1007/s11886-017-0876-4.
   PubMed Web of Science ®Google Scholar
• Kühl JT, Møller JE, Kristensen TS, et al. Left atrial function and mortality in patients with NSTEMI. JACC Cardiovasc Imaging. 2011;4(10):1080–1087. doi: 10.1016/j.jcmg.2011.08.008.
   PubMed Web of Science ®Google Scholar
• Aronson D, Musallam A, Lessick J, et al. Impact of diastolic dysfunction on the development of heart failure in diabetic patients after acute myocardial infarction. Circ Heart Fail. 2010;3(1):125–131. doi: 10.1161/CIRCHEARTFAILURE.109.877340.
   PubMed Web of Science ®Google Scholar
• Lan NSR, Yeap BB, Fegan PG, et al. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging. 2021;37(2):517–527. doi: 10.1007/s10554-020-02034-w.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S14–S31. doi: 10.2337/dc20-S002.
   PubMed Web of Science ®Google Scholar
• Lan NSR, Fegan PG, Rankin JM, et al. Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. Diabet Med. 2019;36(12):1643–1651. doi: 10.1111/dme.14095.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033.
   PubMed Web of Science ®Google Scholar
• Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018;19(6):591–600. doi: 10.1093/ehjci/jey042.
   PubMed Web of Science ®Google Scholar
• Voigt J-U, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16(1):1–11. doi: 10.1093/ehjci/jeu184.
   PubMed Web of Science ®Google Scholar
• Lan NSR, Fegan PG, Yeap BB, et al. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927–935. doi: 10.1002/ehf2.12505.
   PubMed Web of Science ®Google Scholar
• Omar M, Jensen J, Ali M, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol. 2021;6(7):836–840. doi: 10.1001/jamacardio.2020.6827.
   PubMed Web of Science ®Google Scholar
• Cohen ND, Gutman SJ, Briganti EM, et al. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study. Intern Med J. 2019;49(8):1006–1010. doi: 10.1111/imj.14260.
   PubMed Web of Science ®Google Scholar
• Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial? Diabetes Care. 2016;39(12):e212–3–e213. doi: 10.2337/dc16-1312.
   Web of Science ®Google Scholar
• Sareban M, Perz T, Macholz F, et al. Reliability of echocardiographic speckle-tracking derived bi-atrial strain assessment under different hemodynamic conditions. Int J Cardiovasc Imaging. 2017;33(11):1685–1692. doi: 10.1007/s10554-017-1154-7.
   PubMed Web of Science ®Google Scholar
• Singh A, Medvedofsky D, Mediratta A, et al. Peak left atrial strain as a single measure for the non-invasive assessment of left ventricular filling pressures. Int J Cardiovasc Imaging. 2019;35(1):23–32. doi: 10.1007/s10554-018-1425-y.
   PubMed Web of Science ®Google Scholar
• Mălăescu G-G, Mirea O, Capotă R, et al. Left atrial strain determinants during the cardiac phases. JACC Cardiovasc Imaging. 2022;15(3):381–391. doi: 10.1016/j.jcmg.2021.09.009.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Z, Fei H, et al. Left atrial strain reproducibility using vendor-dependent and vendor-independent software. Cardiovasc Ultrasound. 2019;17(1):9. doi: 10.1186/s12947-019-0158-y.
   PubMedGoogle Scholar
• Kim J, Yum B, Palumbo MC, et al. Left atrial strain impairment precedes geometric remodeling as a marker of post-myocardial infarction diastolic dysfunction. JACC Cardiovasc Imaging. 2020;13(10):2099–2113. doi: 10.1016/j.jcmg.2020.05.041.
   PubMed Web of Science ®Google Scholar
• Ida S, Kaneko R, Imataka K, et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Heart Fail Rev. 2021;26(5):1151–1158. doi: 10.1007/s10741-020-09936-w.
   PubMed Web of Science ®Google Scholar